Private: Fullwidth Portfolio Post

17

May2016
On May 5, 2016, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a Recommendations Report on its project on Anti-Vascular Endothelial Growth Factor (VEGF) Drugs for Retinal Conditions. CADTH has undertaken a therapeutic review comparing the clinical effectiveness and relative cost of three anti-VEGF drugs (aflibercept, bevacizumab, ranibizumab) ... Read More

30

Mar2016
Due to a high workload volume and ensuring submissions are reviewed in a timely manner, CADTH is deferring the effective date of the following two CDR procedural revisions: The timing of CDR review team’s responses being provided to the manufacturer, and The revised CDR voluntary withdrawal procedure The revised date for these two ... Read More

30

Mar2016
Recommendation Framework for CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) Programs In collaboration with the participating jurisdictions and with input from stakeholders, CADTH has established a single recommendation framework to support the drug expert committees (the CADTH Canadian Drug Expert Committee [CDEC] and the CADTH pCODR Expert ... Read More

15

Mar2016
The Canadian Agency for Drugs and Technologies in Health (CADTH) posted a call for patient input on  March 11, 2016 for Hospira HealthCare Corporation’s subsequent entry biologic (SEB), INFLECTRA™ (infliximab). According to the CADTH website, Hospira is seeking public reimbursement for Crohn’s disease and Ulcerative Colitis. For those interested in providing ... Read More

10

Mar2016
The Canadian Agency for Drugs and Technologies in Health (CADTH) posted a call for patient input on March 9, 2016 for etanercept - the subsequent entry biologic (SEB) version of Amgen’s ENBREL™. For those interested in providing patient input, please complete the CDR Patient Input Submission. According to the ... Read More

26

Feb2016
Revised Procedures for CDR and pCODR For all drug applications filed for review through either the Common Drug Review (CDR) or pan-Canadian Oncology Drug Review (pCODR) process on or after April 1, 2016, CADTH will no longer accept confidential submitted prices. The submitted price will be disclosed in all applicable CDR ... Read More

02

Feb2016
In November 2015, CADTH received stakeholder feedback on proposed changes to the pan-Canadian Oncology Drug Review (pCODR) program that would allow for broader clinician participation in the pCODR process. Feedback was received from three clinicians, three patient advocacy groups, three pharmaceutical companies, and two industry association groups. This stakeholder feedback ... Read More

14

Dec2015
CADTH is currently updating the third edition of the Guidelines for the Economic Evaluation of Health Technologies: Canada. To help with this initiative, CADTH is inviting interested stakeholders to provide input. These guidelines detail best practices for conducting economic evaluations and are used to standardize and facilitate economic evaluations while ... Read More

26

Oct2015
As requested by stakeholders, the deadline for the following CADTH calls for stakeholder input has been extended to November 9, 2015 at 5:00 p.m. EST: CDR Update – Issue 111 CADTH Consultation: Revisions to the Common Drug Review Procedure Invites stakeholder comments and feedback on the following proposed revisions to the Procedure ... Read More

06

Oct2015
Based on stakeholder feedback received in May 2015, CADTH has announced that in the limited instances where no Canadian patient group exists, individual patient and caregiver input will now be accepted for the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) programs, effective immediately. Please note that for ... Read More